AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24953766
Drug: Sodium valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium valproate 15-20 mg/kg + placebo
Trial: 23161092
Drug: Personalised feedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalised feedback in combination with peer support
Trial: 20600551
Drug: Chitosan treatment
RxNorm normalized name: Chitosan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chitosan treatment at concentrations of 2.5mg/mL and 5.0mg/mL for 60s to 90s
Trial: 20600551
Drug: Chitosan treatment
RxNorm normalized name: Chitosan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chitosan treatment
Trial: 16282843
Drug: Intramuscular testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular testosterone supplementation
Trial: 12121395
Drug: Desonide 0.05%
RxNorm normalized name: DESONIDE 0.05% OINT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desonide 0.05% lotion
Trial: 318952
Drug: Hydrochlorothiazide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (100 mg/day)
Trial: 318952
Drug: Spironolactone (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (400 mg/day)
Trial: 31395295
Drug: L-IVCD
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-IVCD
Trial: 31395295
Drug: LVCD (LBBB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LVCD (LBBB or L-IVCD)
Trial: 21470283
Drug: rhGH (0.067
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH (0.067 mg/kg per day) as daily subcutaneous injections
Trial: 17658525
Drug: 17alpha-hydroxyprogesterone caproate
RxNorm normalized name: 17alpha-Hydroxyprogesterone hexanoate
DrugBank: Hydroxyprogesterone caproate (DB06789)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 17alpha-hydroxyprogesterone caproate (17-HPC) 250 mg, i.m., 1 day before ET
Trial: 11155154
Drug: Low-dose IFNalpha-2b
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose IFNalpha-2b (3 MU) three times weekly for 3 months (Group 2)
Trial: 11155154
Drug: High-dose IFNalpha-2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose IFNalpha-2b (6-10 MU) three times weekly for 3 months (Group 3)
Trial: 11155154
Drug: No specific
RxNorm normalized name: Oregano specific IgE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No specific treatment (Control Group 1)
Trial: 63749
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of 750 mg desferrioxamine before transfusion
Trial: 63749
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of 750 mg desferrioxamine after transfusion
Trial: 63749
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous infusion of 750 mg desferrioxamine over 24 hours
Trial: 63749
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous infusion of desferrioxamine after transfusion
Trial: 63749
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous infusion of 1500 mg desferrioxamine over 24 hours
Trial: 28731567
Drug: Increased global
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Increased global efficiency before starting clinical treatment
Trial: 26648691
Drug: CC +
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC + HMG
Trial: 26648691
Drug: Letrozole +
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole + HMG and CC + HMG
Trial: 26648691
Drug: Letrozole +
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole + HMG, CC + HMG, HMG only
Trial: 14992088
Drug: 2,000 mg
RxNorm normalized name: garlic 2,000 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2,000 mg ascorbic acid intravenously before applying local anesthetics
Trial: 14992088
Drug: 0.5 mg/ml
RxNorm normalized name: urea 0.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/ml ascorbic acid in vitro with o-toluidine
Trial: 14992088
Drug: 5 mg/ml
RxNorm normalized name: urea 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/ml ascorbic acid in vitro with o-toluidine
Trial: 1496538
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (daily 6 g, 30% C20:5 omega‐3 and 20% C22:6 omega‐3 as their methyl esters)
Trial: 1496538
Drug: Coconut oil
RxNorm normalized name: Coconut Oil
DrugBank: Coconut oil (DB14322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coconut oil (daily 6g [63% C8:0 and 36% C10:0])
Trial: 1496538
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (daily 6 g)
Trial: 1496538
Drug: Coconut oil
RxNorm normalized name: Coconut Oil
DrugBank: Coconut oil (DB14322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coconut oil (daily 6g)
Trial: 6363949
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg methylprednisolone (MP) daily for 4 days
Trial: 6363949
Drug: 1,000 mg
RxNorm normalized name: bran 1,000 mg ORAL WAFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg methylprednisolone (MP) daily for 4 days
Trial: 6363949
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg methylprednisolone (MP)
Trial: 6363949
Drug: 1,000 mg
RxNorm normalized name: bran 1,000 mg ORAL WAFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg methylprednisolone (MP)
Trial: 26545539
Drug: Caffeine intake
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine intake (3 mg/kg‐1)
Trial: 16750468
Drug: Cilomilast 15
RxNorm normalized name: CILOMILAST
DrugBank: Cilomilast (DB03849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilomilast 15 mg BID (study 1)
Trial: 16750468
Drug: Cilomilast 15
RxNorm normalized name: CILOMILAST
DrugBank: Cilomilast (DB03849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilomilast 15 mg BID (study 2)
Trial: 14755134
Drug: Reboxetine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reboxetine (4 mg) alone
Trial: 14755134
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of reboxetine (4 mg) and mirtazapine (15 mg)
Trial: 11030508
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin (BTX) injections to the elbow and wrist flexors
Trial: 9085752
Drug: IVUS-guided therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVUS-guided therapy
Trial: 31333252
Drug: Evaluation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evaluation of drug literature abstracts
Trial: 27572887
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (LMWH) - Tinzaparin sodium 4500 IU subcutaneous daily injection with 500 µg folic acid once daily orally, started once positive pregnancy test till the 20th week of gestation.
Trial: 27572887
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid alone (same dosage as in intervention group).
Trial: 22813429
Drug: Ketamine (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (specific dosage and duration not mentioned)
Trial: 21166928
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose atorvastatin (40 mg daily)
Trial: 18359417
Drug: Appropriate empirical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Appropriate empirical antibiotic therapy
Trial: 14499416
Drug: rectal placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rectal placebo (RP)
Trial: 14499416
Drug: rectal lidocaine
RxNorm normalized name: LIDOCAINE 50 mg in 1 g TOPICAL CREAM [Walgreens Anorectal Lidocaine Cream]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rectal lidocaine (RL)
Trial: 14499416
Drug: oral lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral lidocaine (OL)
Trial: 14499416
Drug: rectal nocebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rectal nocebo (RN)
Trial: 9239162
Drug: Granisetron (KYT)
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granisetron (KYT) administered for 5 consecutive days (Group B)
Trial: 9239162
Drug: Granisetron (KYT)
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granisetron (KYT) administered on day 1 (Group A)
Trial: 12959314
Drug: Intramuscular picenadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular picenadol 50 mg
Trial: 3546747
Drug: Discontinue drug
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinue drug therapy and reduce overweight, excess salt, and alcohol (Group 1)
Trial: 3546747
Drug: Discontinue drug
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinue drug therapy with no nutritional program (Group 2)
Trial: 3546747
Drug: Continue drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue drug therapy with no nutritional program (Group 3)
Trial: 29462248
Drug: Platinum-based chemotherapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum-based chemotherapy (PBC)
Trial: 18474682
Drug: Plasma Tanshinol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma Tanshinol (TSL) from cardiotonic pills
Trial: 18474682
Drug: Urinary Tanshinol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary Tanshinol (TSL) from cardiotonic pills
Trial: 18474682
Drug: Absorption rate
RxNorm normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Absorption rate and bioavailability of Tanshinol (TSL)
Trial: 18474682
Drug: Renal excretion
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renal excretion of Tanshinol (TSL)
Trial: 17052637
Drug: Tramadol 50
RxNorm normalized name: traMADol 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 50 mg (1 mL) added to articaine 4%, 1:100:000 epinephrine, 1.5 cartridges (2.7 mL)
Trial: 17052637
Drug: Articaine 4%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Articaine 4%, 1:100:000 epinephrine, 1.5 cartridges (2.7 mL) and saline (1 mL)
Trial: 14603582
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of omeprazole plus diclofenac
Trial: 14603582
Drug: Selective COX‐2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective COX‐2 inhibitor with a PPI or misoprostol
Trial: 7710561
Drug: Hyperglycaemia (14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperglycaemia (14 mmol/l)
Trial: 7710561
Drug: Euglycaemia (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euglycaemia (5 mmol/l)
Trial: 7710561
Drug: Hypoglycaemia (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoglycaemia (2.5 mmol/l)
Trial: 1709903
Drug: Nebulized heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized heparin (800 IU per kg b.w.) administered by inhalation one day prior to surgery
Trial: 1709903
Drug: Nebulized heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized heparin (800 IU per kg b.w.) + long acting anabolic steroid (50 mg nandrolone phenylpropionate) intramuscularly
Trial: 1709903
Drug: 5000 IU
RxNorm normalized name: D 5000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5000 IU heparin subcutaneously on hr prior to surgery and every 12 h for the next 5 postoperative days
Trial: 1709903
Drug: Nebulized heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized heparin (800 IU per kg b.w.)
Trial: 1709903
Drug: Nebulized heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized heparin (800 IU per kg b.w.) + long acting anabolic steroid (50 mg nandrolone phenylpropionate)
Trial: 26695922
Drug: Ambroxol (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambroxol (30 mg three times per day) and Essenciale (600 mg twice daily) for 6 months
Trial: 23756392
Drug: Tianeptine 12.5
RxNorm normalized name: tianeptine 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tianeptine 12.5 mg three times daily for 8 weeks
Trial: 21252141
Drug: efavirenz-based ART
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: efavirenz-based ART (600 mg)
Trial: 21252141
Drug: nevirapine-based ART
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nevirapine-based ART (400 mg)
Trial: 16920865
Drug: Iron+folic acid
RxNorm normalized name: folic acid / iron carbonyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron+folic acid (FeFA) (12.5 mg Fe + 50 mug folic acid)
Trial: 16920865
Drug: Iron+folic acid
RxNorm normalized name: folic acid / iron carbonyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron+folic acid (FeFA) with or without Zinc (Zn) (10 mg)
Trial: 12712025
Drug: Dexamethasone (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.6 mg/kg, maximum dose 10 mg)
Trial: 9255435
Drug: RheothRx Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RheothRx Injection (0.5 mg/ml)
Trial: 9255435
Drug: RheothRx Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RheothRx Injection (1 mg/ml)
Trial: 9255435
Drug: RheothRx Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RheothRx Injection (2 mg/ml)
Trial: 9255435
Drug: RheothRx Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RheothRx Injection (5 mg/ml)
Trial: 9255435
Drug: RheothRx Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RheothRx Injection (during CORE Trial)
Trial: 8345429
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy plus platelet concentrates (10 ml/kg)
Trial: 2942168
Drug: Orally-administered nickel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally-administered nickel (5.6 mg)
Trial: 2942168
Drug: Lower doses
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower doses of nickel
Trial: 22782791
Drug: Duet (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duet (daily use)
Trial: 20593911
Drug: Olmesartan medoxomil
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil 40 mg/HCTZ 12.5 mg
Trial: 20593911
Drug: Up-titration from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up-titration from olmesartan medoxomil 40 mg to olmesartan medoxomil 40 mg/HCTZ 12.5 mg
Trial: 20593911
Drug: Up-titration from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up-titration from olmesartan medoxomil 40 mg/HCTZ 12.5 mg to olmesartan medoxomil 40 mg/HCTZ 25 mg
Trial: 20593911
Drug: Addition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of HCTZ 12.5 mg to olmesartan medoxomil 40 mg
Trial: 20593911
Drug: Continuation on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuation on olmesartan medoxomil 40 mg
Trial: 30672832
Drug: ivabradine (Iva,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ivabradine (Iva, 7.5 mg b.i.d.)
Trial: 20167185
Drug: Telehealth Behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telehealth Behavioral Therapy (TBT) sessions conducted thrice weekly for 12 weeks by phone, lasting an average of 15 minutes each.
Trial: 20167185
Drug: Telehealth Behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telehealth Behavioral Therapy (TBT) sessions.
Trial: 18055037
Drug: Combination fibrinolysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination fibrinolysis with 50 mg alteplase and tirofiban
Trial: 18055037
Drug: Combination fibrinolysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination fibrinolysis
Trial: 8597321
Drug: Fluconazole, 200
RxNorm normalized name: Fluconazole, 200 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole, 200 mg/d for 2 weeks; then fluconazole, 200 mg/d and rifabutin, 300 mg/d for 2 weeks; then rifabutin, 300 mg/d for 2 weeks
Trial: 27712932
Drug: Lidocaine and
RxNorm normalized name: Lidocaine and Tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine and clonidine (15 μg/ml)
Trial: 27712932
Drug: Lidocaine and
RxNorm normalized name: Lidocaine and Tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine and adrenaline (12.5 μg/ml)
Trial: 20305868
Drug: Combination technique
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination technique using Ketac and Cavit
Trial: 17608134
Drug: Hydroxy methyl
RxNorm normalized name: 2-chloro-N-hydroxy methylacetamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxy methyl propyl cellulose based formulation
Trial: 17608134
Drug: Poloxamer based
RxNorm normalized name: Poloxamer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poloxamer based formulation
Trial: 9790154
Drug: Continuation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuation treatment (CT) with clonazepam for another 5 months
Trial: 9790154
Drug: Discontinuation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation treatment (DT) using a clonazepam taper at the rate of 0.25 mg every 2 weeks
Trial: 9790154
Drug: Continuation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuation treatment (CT)
Trial: 9790154
Drug: Discontinuation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation treatment (DT)
Trial: 7815837
Drug: Salvage treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvage treatment after initial induction
Trial: 7815837
Drug: Consolidation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consolidation treatment (standard maintenance, intensive consolidation courses, autologous or allogeneic transplantation)
Trial: 28351410
Drug: Cognitive‐Behavioral Rehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive‐Behavioral Rehabilitation (12 weekly group sessions of 90 min each)
Trial: 26708885
Drug: Adoptive immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adoptive immunotherapy (dendritic cells and cytokine‐induced killer cells, DC‐CIK) combined with chemotherapy
Trial: 26708885
Drug: Adoptive immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adoptive immunotherapy (DC‐CIK) combined with chemotherapy
Trial: 21209881
Drug: Pioglitazone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone treatment
Trial: 16789988
Drug: Cefepime 2G
DrugBank: Cefepime (DB01413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefepime 2G 12 hourly
Trial: 16789988
Drug: Ampicillin/Sulbactam 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin/Sulbactam 3 g 8 hourly and Aztreonam 2 g 8 hourly
Trial: 12832310
Drug: Intensive Therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive Therapy (IT)
Trial: 8842575
Drug: Sodium lactate
RxNorm normalized name: Sodium Lactate
DrugBank: Lactic acid (DB04398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium lactate + Acetazolamide infusion
Trial: 1616890
Drug: 5-fluorouracil (5FU),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil (5FU), 13.5 mg/kg for five days (arm A)
Trial: 1616890
Drug: High-dose folinic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose folinic acid (FA), 200 mg/m2 for five days and 5FU, 400 mg/m2 for five days (arm B)
Trial: 6387968
Drug: Hexoprenaline (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hexoprenaline (10 micrograms administered intravenously 5 minutes before amniocentesis)
Trial: 30682037
Drug: Dengue vaccine
RxNorm normalized name: Dengue vaccine
DrugBank: Dengue tetravalent vaccine, live (DB14764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dengue vaccine with a true VE of 0.8
Trial: 29533864
Drug: Intramuscular oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular oxytocin administration within the first minute following the delivery of the fetus (10 IU)